NCT02021474View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

PHASE2UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Migraine Prophylaxis
Interventions
DRUG

AGX-201

Subcutaneous injection

DRUG

Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).

Subcutaneous injection

Sponsors
All Listed Sponsors
lead

AgoneX Biopharmaceuticals, Inc.

INDUSTRY

NCT02021474 - A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis | Biotech Hunter | Biotech Hunter